Effects of the proteasome inhibitor bortezomib alone, and in combination with chemotherapeutic agents in gastric cancer cell lines

Oncology Reports

Volumn 19, Issue 4, 2008, Pages 1027-1032

  Bae, Sung Hwa ^a   Ryoo, Hun Mo ^a   Kim, Min Kyoung ^b   Lee, Kyung Hee ^b   Sin, Jeong Im ^a   Hyun, Myung Soo ^b  

^a Catholic University of Daegu   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

Author keywords

Apoptosis; Bortezomib; Docetaxel; Gastric cancer; In vitro

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DOCETAXEL; PACLITAXEL; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; TETRAZOLIUM; BORONIC ACID DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PROTEASOME; PYRAZINE DERIVATIVE; TAXOID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL CYCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; WESTERN BLOTTING; CELL PROLIFERATION; CHEMISTRY; DRUG ANTAGONISM; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; STOMACH NEOPLASMS; TAXOIDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 43849086302     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.4.1027     Document Type: Article

References (28)

1. Pisani P, Parkin DM, Bray F and Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29, 1999.
2. Shin HR, Jung KW, Won YJ, Park JG and 139 KCCR-affiliated Hospitals: 2002 Annual Report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 36: 103-114, 2004.
3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Ransch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993.
4. Glimelius B, Hoffmann K, Haglund U, Nyron O and Sjoden PO: Initial or delayed chemotherapy with best supportive in advanced gastric cancer. Ann Oncol 5: 189-190, 1994.
5. Pyrhonen S, Kuitunen T and Kouri M: A randomized, phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer. Br J Cancer 71: 587-591, 1995
6. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999.
7. Almond JB and Cohen GM: The proteasome: a novel target for cancer chemotherapy. Leukemia 16: 433-443, 2002.
8. Drexler HC, Risau W and Konerding MA: Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 14: 65-77, 2000.
9. Twombly R: First proteasome inhibitor approved for multiple myeloma. J Natl Cancer Inst 95: 845, 2003.
10. Fan XM, Wong BC, Qang WP, Zhou XM, Cho CH, Yuen ST, Leung SY, Lin MC, Kung HF and Lam SK: Inhibition of proteasome function induced apoptosis in gastric cancer. Int J Cancer 93: 481-488, 2001.
11. Cusack JC, Liu R, Houston MA, Abendroth K, Elliott PJ, Adams J and Baldwin AS: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic NF-κB Inhibition. Cancer Res 61: 3535-3540, 2001.
12. Bold RJ, Virudachalam S and McConkey DJ: Chemosensitization of pancreatic cancer by inhibition of the 265 proteasome. J Surg Res 100: 11-17, 2001.
13. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J and Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001.
14. Cusack JC: Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib. Cancer Treat Rev 29: 21-31, 2003.
15. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM and Perez-Soler R: Mechanisms of Proteasome inhibitor PS-341-induced G2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9: 1145-1154, 2003.
16. Nawroki ST, Sweeney-Gotsch B, Takamori R and McConkey DJ: The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 31: 59-70, 2004.
17. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA and Berenson JR: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9: 1136-1144, 2003.
18. Montero A, Fossella F, Hortobagyi G and Valero V: Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6: 229-239, 2005.
19. Rajkumar SV, Richardson PG, Hideshima T and Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630-639, 2005.
20. Haldar S, Basu A and Croce CM: Bcl2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1997.
21. You SA, Basu A and Haldar S: Potent antitumor agent proteasome inhibitors: a novel trigger for Bcl-2 phosphorylation to induce apoptosis. Int J Oncol 15: 625-628, 1999.
22. Mortenson MM, Schlieman MG, Virudachalam S, Lara PN, Gandara DG, Davies AM and Bold RJ: Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer. Lung Cancer 49: 163-170, 2005.
23. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495, 1992.
24. Wu X and Levine AJ: p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 91: 3602-3606, 1994.
25. Shinohara K, Tomioka M, Nakano H, Tone S, Ito H and Kawashima S: Apoptosis induction resulting from proteasome inhibition. Biochem J 317: 385-388, 1996.
26. Kitagawa H, Tani E, Ikemoto H, Ozaki I, Nakano A and Omura S: Proteasome inhibitors induce mitochondria-undependent apoptosis in human glioma cells. FEBS Lett 443: 181-186, 1999.
27. Wagenknecht B, Hermisson M, Eitel K and Weller M: Proteasome inhibitors induce p53/p21-independent apoptosis in human glioma cells. Cell Physiol Biochem 9: 117-125, 1999.
28. Uchino S, Noguchi M, Ochidai A, Saito T, Kobayashi M and Hirohashi S: p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 54: 759-764, 1993.